{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T05:10:11Z","timestamp":1746249011061,"version":"3.40.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,5,29]],"date-time":"2014-05-29T00:00:00Z","timestamp":1401321600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s00213-014-3637-8","type":"journal-article","created":{"date-parts":[[2014,5,28]],"date-time":"2014-05-28T15:53:57Z","timestamp":1401292437000},"page":"63-73","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Methylnaltrexone: its pharmacological effects alone and effects on morphine in healthy volunteers"],"prefix":"10.1007","volume":"232","author":[{"given":"James P.","family":"Zacny","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Wroblewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis W.","family":"Coalson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,5,29]]},"reference":[{"key":"3637_CR1","volume-title":"Diagnostic and statistical manual of mental disorders DSM-IV-TR","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders DSM-IV-TR. American Psychiatric Association, Washington, Text revision"},{"key":"3637_CR2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/egh.12.63","volume":"7","author":"S Bader","year":"2013","unstructured":"Bader S, D\u00fcrk T, Becker G (2013) Methylnaltrexone for the treatment of opioid-induced constipation. Expert Review of Gastroenterology & Hepatology 7:13\u201326","journal-title":"Expert Review of Gastroenterology & Hepatology"},{"key":"3637_CR3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00210-007-0146-x","volume":"375","author":"DT Beattie","year":"2007","unstructured":"Beattie DT, Cheruvu M, Mai N, O\u2019Keefe M, Johnson-Rabidoux S, Peterson C et al (2007) The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08\u20130011 and methylnaltrexone. Naunyn-Schmiedeberg\u2019s Archives of Pharmacology 375:205\u2013220","journal-title":"Naunyn-Schmiedeberg\u2019s Archives of Pharmacology"},{"key":"3637_CR4","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jaad.2007.01.007","volume":"56","author":"PL Bigliardi","year":"2007","unstructured":"Bigliardi PL, Stammer H, Jost G, Rufli T, Buchner S, Bigliardi-Qi M (2007) Treatment of pruritis with topically applied opiate receptor antagonist. Journal of the American Academy of Dermatology 56:979\u2013988","journal-title":"Journal of the American Academy of Dermatology"},{"key":"3637_CR5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0028-3908(85)90072-3","volume":"24","author":"DR Brown","year":"1985","unstructured":"Brown DR, Goldberg LI (1985) The use of quaternary narcotic antagonists in opiate research. Neuropharmacology 24:181\u2013191","journal-title":"Neuropharmacology"},{"key":"3637_CR6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1124\/jpet.104.068411","volume":"311","author":"ER Butelman","year":"2004","unstructured":"Butelman ER, Harris TJ, Kreek MJ (2004) Antiallodynic effects of loperamide and fentanyl against topical capsaicin-induced allodynia in unanesthetized primates. Journal of Pharmacology and Experimental Therapeutics 311:155\u2013163","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"3637_CR7","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jpainsymman.2009.02.234","volume":"38","author":"BH Chamberlain","year":"2009","unstructured":"Chamberlain BH, Cross K, Winston JL, Thomas J, Wang W, Su C et al (2009) Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. Journal of Pain and Symptom Management 38:683\u2013690","journal-title":"Journal of Pain and Symptom Management"},{"key":"3637_CR8","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2044.1974.tb00759.x","volume":"29","author":"JM Evans","year":"1974","unstructured":"Evans JM, Hogg MI, Lunn JN, Rosen M (1974) A comparative study of the narcotic against activity of naloxone and levallorphan. Anaesthesia 29:721\u2013727","journal-title":"Anaesthesia"},{"key":"3637_CR9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/009127009703700105","volume":"37","author":"JF Foss","year":"1997","unstructured":"Foss JF, O\u2019Connor MF, Yuan CS, Murphy M, Moss J, Roizen MF (1997) Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study. Journal of Clinical Pharmacology 37:25\u201330","journal-title":"Journal of Clinical Pharmacology"},{"key":"3637_CR10","first-page":"29","volume":"13","author":"HF Fraser","year":"1961","unstructured":"Fraser HF, Isbell H (1961) Human pharmacology and addictiveness of ethyl 1-(3-cyano-3,3-phenylpropyl)-4-phenyl-4-piperadine carboxylate hydrochloride. Bulletin on Narcotics 13:29\u201343","journal-title":"Bulletin on Narcotics"},{"key":"3637_CR11","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0022-3565(25)26118-3","volume":"133","author":"HF Fraser","year":"1961","unstructured":"Fraser HF, van Horn GD, Martin WR, Wolbach AB, Isbell H (1961) Methods for evaluating addiction liability. (a) \u201cattitude\u201d of opiate addicts toward opiate-like drugs, (b) a short-term \u201cdirect\u201d addiction test. Journal of Pharmacology and Experimental Therapeutics 133:371\u2013387","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"3637_CR12","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2165\/11204520-000000000-00000","volume":"70","author":"KP Garnock-Jones","year":"2010","unstructured":"Garnock-Jones KP, McKeage K (2010) Methylnaltrexone. Drugs 70:919\u2013928","journal-title":"Drugs"},{"key":"3637_CR13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/11598000-000000000-00000","volume":"32","author":"A Gatti","year":"2012","unstructured":"Gatti A, Sabato AF (2012) Management of opioid-induced constipation in cancer patients: focus on methylnaltrexone. Clinical Drug Investigation 32:293\u2013301","journal-title":"Clinical Drug Investigation"},{"key":"3637_CR14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2466\/pr0.1966.18.1.163","volume":"18","author":"CA Haertzen","year":"1966","unstructured":"Haertzen CA (1966) Development of scales based on patterns of drug effects, using the Addiction Research Center Inventory (ARCI). Psychological Reports 18:163\u2013194","journal-title":"Psychological Reports"},{"key":"3637_CR15","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/bmj.3.5715.132","volume":"3","author":"JG Hannington-Kiff","year":"1970","unstructured":"Hannington-Kiff JG (1970) Measurement of recovery from outpatient general anaesthesia with a simple ocular test. British Medical Journal 3:132\u2013135","journal-title":"British Medical Journal"},{"key":"3637_CR16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.regpep.2009.03.012","volume":"155","author":"P Holzer","year":"2009","unstructured":"Holzer P (2009) Opioid receptors in the gastrointestinal tract. Regulatory Peptides 155:11\u201317","journal-title":"Regulatory Peptides"},{"key":"3637_CR17","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0022-3565(25)27721-7","volume":"157","author":"DR Jasinski","year":"1967","unstructured":"Jasinski DR, Martin WR, Haertzen CA (1967) The human pharmacology and abuse potential of N-allylnoroxymorphone (naloxone). Journal of Pharmacology and Experimental Therapeutics 157:420\u2013426","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"3637_CR18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11060-009-9863-y","volume":"94","author":"RE Kast","year":"2009","unstructured":"Kast RE (2009) Use of FDA approved methamphetamine to allow adjunctive use of methylnaltrexone to mediate core anti-growth factor signaling effects in glioblastoma. Journal of Neuro-Oncology 94:163\u2013167","journal-title":"Journal of Neuro-Oncology"},{"key":"3637_CR19","first-page":"232","volume":"25","author":"A Korey","year":"1979","unstructured":"Korey A, Zilm DH, Sellers EM (1979) A comparison of the dependence liabilities of two antidiarrheal agents, nufenoxole and loperamide, in volunteer subjects (abstract). Clinical Pharmacology and Therapeutics 25:232","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"3637_CR20","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/0091-3057(88)90128-1","volume":"30","author":"KM Kumor","year":"1988","unstructured":"Kumor KM, Haertzen CA, Jasinski DR, Johnson RE (1988) The psychopharmacologic and prolactin response after large doses of naloxone in man. Pharmacology, Biochemistry, and Behavior 30:967\u2013975","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"3637_CR21","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0022-3565(25)30077-7","volume":"192","author":"HK Lee","year":"1975","unstructured":"Lee HK, Wang SC (1975) Mechanism of morphine-induced miosis in the dog. Journal of Pharmacology and Experimental Therapeutics 192:415\u2013431","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"3637_CR22","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/00000542-198905000-00008","volume":"70","author":"JH Levy","year":"1989","unstructured":"Levy JH, Brister NW, Shearin A, Ziegler J, Hug CC, Adelson DM et al (1989) Wheal and flare responses to opioids in humans. Anesthesiology 70:756\u2013760","journal-title":"Anesthesiology"},{"issue":"2","key":"3637_CR23","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/BF02244141","volume":"101","author":"N Loimer","year":"1990","unstructured":"Loimer N, Schmid R, Gr\u00fcnberger J, Linzmayer L (1990) Naloxone induces miosis in normal subjects. Psychopharmacology 101(2):282\u2013283","journal-title":"Psychopharmacology"},{"key":"3637_CR24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00008571-200201000-00002","volume":"12","author":"J L\u00f6tsch","year":"2002","unstructured":"L\u00f6tsch J, Skarke C, Gr\u00f6sch S, Darimont J, Schmidt H, Geisslinger G (2002) The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 12:3\u20139","journal-title":"Pharmacogenetics"},{"key":"3637_CR25","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/cpt1971122part1245","volume":"12","author":"WR Martin","year":"1971","unstructured":"Martin WR, Sloan JW, Sapira JD, Jasinski DR (1971) Physiologic, subjective and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clinical Pharmacology and Therapeutics 12:245\u2013258","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"3637_CR26","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/00000542-199710000-00008","volume":"87","author":"DB Murphy","year":"1997","unstructured":"Murphy DB, Sutton JA, Prescott LF, Murphy MB (1997) Opioid-induced delay in gastric emptying: a peripheral mechanism in humans. Anesthesiology 87:765\u2013770","journal-title":"Anesthesiology"},{"key":"3637_CR27","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/0024-3205(83)90123-6","volume":"33","author":"RB Murray","year":"1983","unstructured":"Murray RB, Adler MW, Korczyn AD (1983) The pupillary effects of opioids. Life Sciences 33:495\u2013509","journal-title":"Life Sciences"},{"key":"3637_CR28","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jpainsymman.2007.12.005","volume":"35","author":"RK Portenoy","year":"2008","unstructured":"Portenoy RK, Thomas J, Boatwright MLM, Tran D, Galasso FL, Stambler N et al (2008) Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. Journal of Pain and Symptom Management 35:458\u2013468","journal-title":"Journal of Pain and Symptom Management"},{"key":"3637_CR29","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0022-3565(25)21335-0","volume":"250","author":"KL Preston","year":"1989","unstructured":"Preston KL, Bigelow GE, Bickel WK, Liebson IA (1989) Drug discrimination in human postaddicts: agonist\u2013antagonist opioids. Journal of Pharmacology and Experimental Therapeutics 250:184\u2013196","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"3637_CR30","doi-asserted-by":"crossref","first-page":"9268","DOI":"10.1073\/pnas.1018699108","volume":"108","author":"R Ray","year":"2011","unstructured":"Ray R, Ruparel K, Newberg A, Wileyto EP, Loughead JW, Divgi C et al (2011) Human mu opioid receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proceedings of the National Academy of Sciences of the United States of America 108:9268\u20139273","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"3637_CR31","first-page":"521","volume-title":"Goodman and Gilman\u2019s The pharmacological basis of therapeutics","author":"T Reisine","year":"1996","unstructured":"Reisine T, Pasternak G (1996) Opioid analgesics and antagonists. In: Hardman JG, Gilman AG, Limbird LE (eds) Goodman and Gilman\u2019s The pharmacological basis of therapeutics. McGraw-Hill, New York, pp 521\u2013555"},{"key":"3637_CR32","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/sj.clpt.6100164","volume":"82","author":"CE Rosow","year":"2007","unstructured":"Rosow CE, Gomery P, Chen TY, Stefanovich P, Stambler N, Israel R (2007) Reversal of opioid-induced bladder dysfunction by intravenous naloxone and methylnaltrexone. Clinical Pharmacology and Therapeutics 82:48\u201353","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"3637_CR33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.CIR.63.1.117","volume":"63","author":"P Rubin","year":"1981","unstructured":"Rubin P, Blaschke TF, Guilleminault C (1981) Effect of naloxone, a specific opioid inhibitor, on blood pressure fall during sleep. Circulation 63:117\u2013121","journal-title":"Circulation"},{"key":"3637_CR34","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0014-2999(82)90026-7","volume":"78","author":"J Russell","year":"1982","unstructured":"Russell J, Bass P, Goldberg LI, Schuster CR, Merz H (1982) Antagonism of gut, but not central effects of morphine with quaternary opiate antagonists. European Journal of Pharmacology 78:255\u2013261","journal-title":"European Journal of Pharmacology"},{"key":"3637_CR35","first-page":"39","volume":"7","author":"N Slatkin","year":"2009","unstructured":"Slatkin N, Thomas J, Lipman AG, Wilson G, Boatwright ML, Wellman C et al (2009) Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. Journal of Supportive Oncology 7:39\u201346","journal-title":"Journal of Supportive Oncology"},{"key":"3637_CR36","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1056\/NEJMoa0707377","volume":"358","author":"J Thomas","year":"2008","unstructured":"Thomas J, Karver S, Cooney GA, Chamberlain BH, Watt CK, Slatkin NE et al (2008) Methylnaltrexone for opioid-induced constipation in advanced illness. NEJM 358:2332\u20132343","journal-title":"NEJM"},{"key":"3637_CR37","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0166-4328(89)80049-X","volume":"33","author":"KA Trujillo","year":"1989","unstructured":"Trujillo KA, Belluzzi JD, Stein L (1989) Effects of opiate antagonists and their quaternary analogues on nucleus accumbens self-stimulation. Behavioural Brain Research 33:181\u2013188","journal-title":"Behavioural Brain Research"},{"key":"3637_CR38","doi-asserted-by":"crossref","DOI":"10.1037\/11167-000","volume-title":"The measurement and appraisal of adult intelligence","author":"D Wechsler","year":"1958","unstructured":"Wechsler D (1958) The measurement and appraisal of adult intelligence. Williams and Wilkins, Baltimore"},{"key":"3637_CR39","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/MCG.0b013e31821100ab","volume":"45","author":"LB Weinstock","year":"2011","unstructured":"Weinstock LB, Chang AC (2011) Methylnaltrexone for treatment of acute colonic pseudo-obstruction. Journal of Clinical Gastroenterology 45:883\u2013884","journal-title":"Journal of Clinical Gastroenterology"},{"key":"3637_CR40","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0028-3908(79)90072-8","volume":"18","author":"JC Willer","year":"1979","unstructured":"Willer JC, Boreau F, Dauthier C, Bonora M (1979) Study of naloxone in normal awake man: effects on heart rate and respiration. Neuropharmacology 18:469\u2013472","journal-title":"Neuropharmacology"},{"key":"3637_CR41","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ejphar.2010.07.039","volume":"649","author":"A Yamamoto","year":"2010","unstructured":"Yamamoto A, Sugimoto Y (2010) Involvement of peripheral mu opioid receptors in scratching behavior in mice. European Journal of Pharmacology 649:336\u2013341","journal-title":"European Journal of Pharmacology"},{"key":"3637_CR42","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0028-3908(98)00192-0","volume":"38","author":"C-S Yuan","year":"1999","unstructured":"Yuan C-S, Foss JF (1999) Gastric effects of methylnaltrexone on mu, kappa, and delta opioid agonists induced brainstem unitary responses. Neuropharmacology 38:425\u2013432","journal-title":"Neuropharmacology"},{"key":"3637_CR43","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0009-9236(96)90117-4","volume":"59","author":"C-S Yuan","year":"1996","unstructured":"Yuan C-S, Foss JF, O\u2019Connor M, Toledano A, Roizen MF, Moss J (1996) Methylnaltrexone prevents morphine-induced delay in oral\u2013cecal transit time without affecting analgesia: a double-blind, randomized placebo-controlled trial. Clinical Pharmacology and Therapeutics 59:469\u2013475","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"3637_CR44","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0376-8716(98)00087-8","volume":"52","author":"C-S Yuan","year":"1998","unstructured":"Yuan C-S, Foss JF, O\u2019Connor M, Osinski J, Roizen MF, Moss J (1998) Efficacy of orally administered methylnaltrexone in decreasing subjective effects after intravenous morphine. Drug and Alcohol Dependence 52:161\u2013165","journal-title":"Drug and Alcohol Dependence"},{"key":"3637_CR45","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1001\/jama.283.3.367","volume":"283","author":"CS Yuan","year":"2000","unstructured":"Yuan CS, Foss JF, O\u2019Connor M, Osinski J, Karrison T, Moss J et al (2000) Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA 283:367\u2013372","journal-title":"JAMA"},{"key":"3637_CR46","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1124\/jpet.300.1.118","volume":"300","author":"C-S Yuan","year":"2002","unstructured":"Yuan C-S, Wei G, Foss JF, O\u2019Connor M, Karrison T, Osinski J (2002) Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. Journal of Pharmacology and Experimental Therapeutics 300:118\u2013123","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"3637_CR47","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1177\/0091270004273491","volume":"45","author":"CS Yuan","year":"2005","unstructured":"Yuan CS, Doshan H, Charney MR, O\u2019Connor M, Karrison T, Maleckar SA et al (2005) Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. Journal of Clinical Pharmacology 45:538\u2013546","journal-title":"Journal of Clinical Pharmacology"},{"key":"3637_CR48","author":"F Zand","year":"2014","unstructured":"Zand F, Amini A, Asadi S, Farbood A (2014) The effect of methylnaltrexone on the side effects of intrathecal morphine after orthopedic surgery under spinal anesthesia. Pain Practice. doi: 10.1111\/papr.12185","journal-title":"Pain Practice"},{"key":"3637_CR49","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/0028-3908(80)90031-3","volume":"19","author":"DH Zilm","year":"1980","unstructured":"Zilm DH (1980) Naloxone response in non-dependent man: effect on six physiological variables. Neuropharmacology 19:591\u2013595","journal-title":"Neuropharmacology"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-014-3637-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-014-3637-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-014-3637-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T04:38:10Z","timestamp":1746247090000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-014-3637-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,29]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["3637"],"URL":"https:\/\/doi.org\/10.1007\/s00213-014-3637-8","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"type":"print","value":"0033-3158"},{"type":"electronic","value":"1432-2072"}],"subject":[],"published":{"date-parts":[[2014,5,29]]}}}